By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Asuragen today said that it has signed a collaboration with Affymetrix to develop RNA Control Kits for molecular diagnostic applications.

Under the agreement, Asuragen will develop and manufacture the kits, which are intended for use with in vitro transcription reagent kits for clinical molecular diagnostic applications, for Affymetrix. The Austin, Texas-based firm said that the kits will enable Affy to supply its molecular diagnostic partners with complete solutions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.